Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
59
-
Total 13F shares, excl. options
-
10M
-
Shares change
-
+343K
-
Total reported value, excl. options
-
$179M
-
Value change
-
+$6.2M
-
Number of buys
-
37
-
Number of sells
-
-7
-
Price
-
$17.87
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q3 2017
64 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q3 2017.
CRISPR Therapeutics AG - Common Stock (CRSP) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10M shares
of 86M outstanding shares and own 11.68% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (3.22M shares), Abingworth LLP (1.97M shares), CLOUGH CAPITAL PARTNERS L P (780K shares), FRANKLIN RESOURCES INC (729K shares), Global Thematic Partners, LLC (570K shares), New Leaf Venture Partners, L.L.C. (528K shares), ORBIMED ADVISORS LLC (372K shares), GRANAHAN INVESTMENT MANAGEMENT INC/MA (264K shares), Novo Holdings A/S (223K shares), and PRICE T ROWE ASSOCIATES INC /MD/ (152K shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.